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Aim:    To identify the problems of pegylated interferon (PEG-IFN) with ribavirin 
therapy against hepatitis C virus (HCV) reinfection in living donor liver transplantation 
(LDLT) patients. HCV kinetics during the PEG-IFN with ribavirin therapy were 
analyzed in LDLT patients, as well as in chronic hepatitis C (CHC) patients. 
Methods:    The study included 80 consecutive HCV infected patients undergoing 
PEG-IFN with ribavirin therapy (64 CHC and 16 LDLT patients) who attended the 
Nagasaki University Hospital for an initial visit between January 2005 and December 
2007. 
Results:    The sustained viral response (VR) rate of the CHC group (80%) was superior 
to the LDLT group (22%). The viral disappearance rate of the CHC group was also 
superior to the LDLT group, regardless of the HCV serotype. The HCV core antigen 
(cAg) titer under treatment in the LDLT group was more than that of the CHC group 
from day 0 to week 12. The HCV core antigen (cAg) decrease rate of the LDLT group 
on the first day of treatment was less than that of the CHC group. 
Conclusion:    The HCV infection of a transplanted liver is more refractory to treatment 
than a non-transplanted liver. The low reduction HCV cAg rate on day 1 is one of the 
problems of the combination therapy. 
Key words:    chronic hepatitis C, first phase, hepatitis C virus, interferon, living donor 
liver transplantation 
<H1>INTRODUCTION 
HEPATITIS C VIRUS (HCV) infection is widespread throughout the world. Chronic 
HCV infection leads to cirrhosis and hepatocellular carcinoma. Liver transplantation 
for HCV-related liver disease has been an option worldwide.1 Recently, it has been 
shown that the prognosis for liver transplanted (LT) patients with HCV-related disease 
deteriorates over time,2 thus resulting in a poorer outcome than in the non-HCV 
course.3 The transplanted liver for HCV-related disease undergoes a rapidly progressive 
fibrosis and acute graft failure.3,4 Consequently, anti-HCV treatment after LT is 
important for the prognosis. Interferon (IFN) has been recognized as the only treatment 
method for HCV infection. For the transplanted liver, it is known that IFN treatment 
improves liver fibrosis or halts the progression.5 Recently, the combination of pegylated 
IFN (PEG-IFN) with ribavirin was used and produced an excellent result for 
non-transplanted patients with HCV.6 However, that was not the case for the HCV 
re-infected transplanted liver.7 It is important that the cause of refractory HCV infection 
in the transplanted liver be more fully clarified. Immunosuppressant therapy, especially 
with glucocorticoid, has been speculated to be the cause of the refractory nature of the 
transplanted liver to IFN.8,9 The cause of this is considered to be that glucocorticoid 
downregulated the IFN signal transduction in the hepatocytes.8 The authors recently 
found that calcineurin inhibitors also inhibited IFN induced STAT-1 phosphorylation 
and antiviral activity in the HCV replicon system.10 Therefore, the problem of IFN 
signaling in the hepatocyte induced an IFN refractory condition11 and decreased the 
first phase of HCV decline, which was IFN induced HCV decay during the first day of 
IFN treatment.12 
 In the present study, we attempted to better understand PEG-IFN and ribavirin 
therapy by comparing patients with chronic hepatitis from HCV infection (CHC) with 
living donor LT (LDLT) patients. When the non-transplanted CHC patients were used 
as a reference against the HCV reinfected LDLT patients, we expected that the 
differences in the clinical data in the two groups would help to clarify the problem of 
IFN refractory HCV infection, and shed light on the analysis of HCV kinetics under 
IFN and ribavirin treatment, and to elucidate the damaged segment of the IFN induced 
antiviral mechanism in the LDLT condition. 
<H1>PATIENTS AND METHODS 
<H2>Patients 
THE PRESENT RESEARCH is a prospective study. The study included 80 
consecutive HCV-infected patients undergoing PEG-IFN with ribavirin combination 
therapy (64 CHC and 16 LDLT patients) who attended the Nagasaki University 
Hospital for an initial visit between January 2005 and December 2007. All patients 
received the targeted dose of 1.5 g/kg PEG-IFN--2b (Pegintron; Schering-Prough 
K.K., Osaka, Japan) once weekly with daily ribavirin (Rebetol; Schering-Plough K.K., 
Osaka, Japan) for a total dose of 600 mg (bodyweight < 60 kg), 800 mg 
(60 kg < bodyweight < 80 kg) or 1000 mg (bodyweight > 80 kg) according to 
bodyweight (BW). The number of patients who were judged to have obtained a 
curative effect from IFN therapy was 42 in total and 12 in LDLT patients. If the 
HCV-RNA had been negative in the patient serum until 12 weeks after the initiation of 
treatment or positive at 24 weeks, PEG-IFN with ribavirin therapy was stopped at 
week 48. If the HCV-RNA had been negative from weeks 12 to 24, PEG-IFN with 
ribavirin therapy was continued for 24 weeks to a predetermined 48 weeks. CHC 
patients were diagnosed on the basis of a persistently raised alanine aminotransferase 
(ALT) level and biopsy proven disease. All LDLT patients, who had undergone liver 
transplantation for HCV related cirrhosis at Nagasaki University Hospital from June 
2002 to May 2007, had the HCV-RNA in their serum at the commencement of 
PEG-IFN with ribavirin treatment. To prevent HCV related hepatitis after liver 
transplantation, pre-emptive therapy using IFN is the strategy used at the Nagasaki 
University Hospital. After the recovery of the general condition without ascites and 
icterus after transplantation, and establishment of the diagnosis using the liver biopsy, 
PEG-IFN with ribavirin therapy was started. The interval between LDLT and IFN 
treatment was a mean of 281 days (range 16–989 days). Tacrolimus (Astellas, Tokyo, 
Japan) an immunosuppressive agent, was used together with steroids for all LDLT 
patients as the induction therapy. When IFN therapy was commenced, tacrolimus was 
switched to cyclosporine (Novartis, Tokyo, Japan) in 12/16 cases. A percutaneous liver 
biopsy assisted by ultrasonography was carried out in all cases. Liver histology was 
evaluated according to the degree of fibrosis and necroinflammatory activity.13 The 
extent of fibrosis (staging) was classified as follows: F1 (periportal expansion), F2 
(portoportal septa), F3 (portocentral linkage or bridging fibrosis) and F4 (cirrhosis). 
The necroinflammatory activity (grading) was classified as follows: A1 (mild), A2 
(moderate) and A3 (severe). Liver biopsy specimens were fixed in 10% formalin, 
embedded in paraffin, cut to a thickness of 4 m, and subjected to hematoxylin–eosin 
and Azan–Mallory staining. 
<H2>Hepatitis C virus kinetics assessment 
We compared the HCV viral load in both groups, determined by the HCV core antigen 
(cAg), at baseline (D0), day 1 (D1), week 1 (W1), week 2 (W2), week 4 (W4), week 8 
(W8), week 12 (W12), week 24 (W24) and week 48 (W48). The HCV viral serotype 
(ST) and HCV core antigen (cAg) were determined using available kits. In this assay, 
HCV serotypes 1 and 2 correspond to genotypes 1 and 2 of Simmonds’ classification,14 
respectively. The HCV cAg correlates with HCV-RNA by quantitative PCR.15 HCV 
cAg was measured at the indicated times and HCV-RNA qualitative PCR, the amplicor 
monitor method, was used after the level was under the detection range of HCV cAg in 
every month. In the present study, we proposed the calculation of the decreased HCV 
viral load during PEG-IFN with ribavirin treatment and set as follows: a negative HCV 
cAg was 20 fmol/L and a negative HCV-RNA qualitative PCR was 1 fmol/L. 
<H2>Clinical and laboratory measurements 
The body mass index (BMI) was calculated as weight (kg) divided by the square of 
height (m). Subjects fasted overnight before blood samples were obtained. Venous 
plasma glucose was measured with an automated analyzer, and basal serum insulin was 
measured using a standard radioimmunoassay. The index of insulin resistance and 
-cell function was calculated using the fasting value of plasma glucose (we excluded 
the patients with greater than 130 mg/dL), and the serum insulin level according to the 
homeostasis model assessment (HOMA) method. HOMA-IR, an insulin resistance 
marker, is calculated as follows: fasting plasma glucose × fasting insulin/405. 
HOMA-, a -cell function marker, was calculated as follows: 360 × fasting 
insulin/(fasting plasma glucose-63).16 White blood cell, red blood cell, platelet, 
hemoglobin A1c, ALT, aspartate aminotransferase (AST), -GTP, total cholesterol 
(TC), triglyceride (TG), Low density lipoprotein (LDL), High density lipoprotein 
(HDL), free fatty acid (FFA), and ferritin were determined by standard hematometry 
and laboratory techniques. 
<H2>Statistical analysis 
The data were processed on a personal computer and analyzed using StatView 5.0 
(SAS Institute, Cary, NC, USA). Differences between groups were analyzed by 
Mann–Whitney U-test and Pearson 2-test. All data in the text and tables are shown as 
means, unless otherwise indicated. The statistical analysis of the HCV-RNA 
disappearance rate was by the Kaplan–Meier method with Wilcoxon assay. Values of 
P < 0.05 were considered to be statistically significant. 
<H1>RESULTS 
<H2>Differences of patient characteristics 
FIRST, THE PRETREATMENT clinical and laboratory characteristics were compared 
with All-CHC and All-LDLT patients (Table 1). The BW and BMI in the All-CHC 
group were higher than that of the All-LDLT group. Therefore, the levels of PEG-IFN 
dose per BW and ribavirin dose per BW were even, but the levels of PEG-IFN dose and 
ribavirin dose in the all LDLT group were lower than in the All-CHC group. The HCV 
viral load in the all LDLT group was greater than that in the All-CHC group and 
serotype 1 was the majority in the All-LDLT group. In hematology and laboratory data, 
the red blood cell count and hemoglobin in the All-LDLT group was lower than that of 
the All-CHC group, and the FFA level was higher in the All-LDLT group. In the 
histological examination, fibrosis is more advanced in the All-CHC group than in the 
All-LDLT group. There was the tendency toward higher levels of fasting plasma 
glucose and lower levels of HOMA- in the All-LDLT group than in the All-CHC 
group. Next, we targeted the serotype 1 and a high HCV titer (ST1H group) above 
100 KIU/L by the qualitative PCR method or 300 fmol/L of the cAg assay. These were 
examined in the same way (Table 2). The ST1H group might have shown the same 
result as the All group, except the levels of fasting plasma glucose and HOMA- did 
not differ with ST1H-CHC and ST1H-LDLT. The mean value of fasting plasma 
glucose (FPG) was higher than the normal range in the LDLT group. The 
discontinuance rates of treatment were almost equal, 19 cases (29.7%) and 4 cases 
(25%) in All-CHC and All-LDLT, respectively. The reasons for discontinuance were 
adverse effects in All-LDLT patients and the refractory nature of viral response in two 
All-CHC patients. 
<H2>The HCV infection in the LDLT group is more obstinate than in the CHC 
group 
The response rate and cure rate of PEG-IFN with ribavirin therapy were compared with 
both groups (Table 2A, All group and B, ST1H group). The HCV response rate to 
treatment, viral response (VR), was determined by the disappearance of HCV-RNA or 
by the decline of HCV cAg to less than 1/100 before treatment. The cure rate, sustained 
viral response rate (SVR), was determined by a negative HCV-RNA by qualitative 
PCR method at 6 months post-termination of treatment. The VR rate at 8 and 12 weeks, 
but not at 4 weeks, and the PP-SVR in the LDLT group (Table 3A,B) was worse than 
that in the CHC group. Non-viral responders, who did not achieve HCV-RNA 
negativity during the treatment, did not show statistical significance in either SG1H 
group (Table 3B). As a result, we calculated the prediction of the lack of SVR by 
non-viral response in the LDLT group. The sensitivity, specificity, positive predictive 
values and negative predictive value were 1, 0, 0.917 and the acalculia for null viral 
responders at 24 h, 0.7, 1, 1 and 0.25 at 4 weeks, 0.6, 1, 1 and 0.2 at 8 weeks, 0.6, 1, 1 
and 0.2 at 12 weeks, respectively. 
 The disappearance rate of HCV-RNA was evaluated by the Kaplan–Meier 
method (Fig. 1 ST1H group). The disappearance rate in the LDLT group was 
statistically lower than the CHC group. Before 14 weeks after the initiation of treatment, 
the HCV-RNA disappearance case was not apparent in the ST1H group (Fig. 1). 
<H2>The decline of HCV load, especially early phase, is blocked in the LDLT 
group 
For the analysis of viral kinetics, we evaluated the decline of the HCV load and the 
decline rate after treatment with particular emphasis of the early phase of treatment, 
including D1-W12. In the ST1H group (Fig. 2), the decreased rate on D1 in the LDLT 
group was statistically lower than CHC (Fig. 2b) and the viral load of the LDLT group 
was larger than that in CHC from D0 to W12 (Fig. 2a). The decreased rate at the 
indicated time without D1 and W12 was not the difference between CHC and LDLT 
(Fig. 2b). We next analyzed the SG1H-group that matched the pre-treatment HCV cAg 
titer (Fig. 3). In a similar fashion to Figure 2, the viral load of the matched LDLT group 
was larger than that of the matched CHC from D1 to W12 (Fig. 3a) and the decreased 
rate of the matched LDLT group was lower than that of the matched CHC at D1, W2 
and W4 (Fig. 3b). 
<H1>DISCUSSION 
IN THE PRESENT prospective study, we compared CHC and LDLT patients treated 
with PEG-IFN and ribavirin for HCV infection. BMI, HCV cAg, red blood cell, -GTP, 
FFA and liver fibrosis in the pretreatment clinical characteristics were different in both 
groups (Tables 1,2). The VR rate of the CHC group was superior to that of the LDLT 
group, and the SVR by per-protocol analysis was also similar in result to the VR 
(Table 3). The viral disappearance rate of the CHC group was superior to the LDLT 
group, regardless of the HCV serotype (Fig. 1). The HCV cAg titer under the treatment 
in the LDLT group was more than that of the CHC group from D0 to W12 (Figs 2a,3a) 
and the HCV cAg decrease rate of the LDLT group at the D1 was less than that of the 
CHC group (Figs 2b,3b). We showed that the reinfected HCV to the graft liver was 
more refractory than the non-transplanted CHC. The PEG-IFN and ribavirin dose per 
BW was an equal dose in both groups. However, it was difficult to determine the 
pretreatment predictive factors for the LDLT cases, because only one case showed SVR 
in the LDLT group. Thus, we considered that the difference of the pretreatment clinical 
characteristics in both groups might be related to the refractory HCV infection. 
The pretreated HCV cAg titer is known to be the principal factor for IFN 
resistance. For CHC and LDLT patients, a high HCV-RNA titer in the pretreatment sera 
is associated with non-responder status for IFN treatment.7,17 In the LDLT condition, 
the HCV-RNA titer was rapidly increased after immediately decreasing at transplant 
and the viral load after several weeks post-LDLT exceeded the value of pre-LDLT.18 
The HCV-RNA titer increased rapidly in patients receiving corticosteroids as part of the 
immunosuppressant regimen.18,19 We have speculated that the massive amount of HCV, 
caused by immunosuppressant therapy after the LDLT, was part of the reason for the 
IFN refractory status. However, comparisons with the pretreated HCV cAg matched 
groups (Fig. 3) showed the existence of an important factor other than the pretreatment 
viral load. It will, therefore, be necessary to analyze this problem by evaluating many 
factors, for example immunosuppressants10 and regeneration, in the future. 
A high level of -GTP was also known to be an important factor for IFN 
treatment.7,17 Usually, high levels of -GTP and FFA have been linked to insulin 
resistance.20,21 Therefore, insulin resistance in the liver is assumed in the condition of 
IFN resistance. However, the LDLT group had the normal range of HOMA-IR,16 which 
was lower than that of the CHC group (Tables 1,2). The HCV infection after liver 
transplantation is associated with insulin resistance.22 Immunosuppressants, especially 
corticosteroids, induced insulin resistance.23 In the present study, the LDLT group had a 
disturbance of insulin secretion rather than insulin resistance and high levels of FPG 
might be caused by the disturbance of insulin secretion. Therefore, further study is 
necessary to clarify the relationship between the glucose metabolism and the IFN 
resistance in LDLT patients. The levels of -GTP rise at cholestatic conditions. It was 
reported that the presence of a cholestatic profile is associated with an adverse response 
to IFN treatment in LT.7 A cholestatic profile provoked the TH2-like lymphocyte 
response.19 The authors have previously reported that IL-10, representative of TH2 
cytokine, inhibits IFN signaling through inducible suppressor of cytokine signaling 
(SOCS).24 The high levels of FFA were induced by a catabolic state, such as cirrhosis, 
and were not fully recovered after LDLT. As a result, the levels of FFA reflected a 
continuous catabolic state at the beginning of IFN treatment. FFA can induce oxidative 
stress in various cells,25,26 and inhibit the IFN induced antiviral gene induction through 
the inactivation of Jak-1 and Tyk-2.27 Therefore, we are speculating that high levels of 
-GTP and FFA in the LDLT group have the ability to inhibit IFN signaling as much as 
in the CHC patients. 
We are paying attention to the viral decline of D1/D0 (Figs 2b,3b). The decreased 
rate of D1 is named as the first phase of HCV decline and is the predictor of SVR.28,29 
The first phase influenced the second phase, which is the decline of HCV after D2.28 
The IFN induced antiviral gene products were considered to be very important for 
antiviral activity.11 The expressions of the IFN stimulating genes (ISG) were associated 
with the early phase of the decline11 and it was reported that the lack of ISG caused 
early liver fibrosis in the LT patients with HCV.30 In the LDLT group, the reduced HCV 
cAg decreased the rate of D1 and this might be part of the cause of being IFN 
resistance. We speculate that an IFN signaling disturbance, related to high levels of 
-GTP and FFA, might have triggered the adverse effect to the HCV cAg decreased rate 
of D1. 
In summary, it became clear that the viral response and SVR is worse in the 
LDLT group. The first phase of viral decay, the decreased rate of D1/D0, also declined 
in the LDLT group. High levels of -GTP and FFA in the pretreatment sera might also 
be related to IFN-signaling damage in hepatocytes. At the initiation of pre-emptive 
therapy, HCV had also been increasing in the graft liver and the catabolic status of 
energy did not recover for the relatively small size of the graft liver. When beginning 
treatment for an HCV infection after LT, we should carefully take into account the 
timing of IFN initiation, in addition to the types of immunosuppressants used. 
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Figure 1    The difference in the HCV-RNA disappearance rate between chronic the 
hepatitis C (CHC) group and living donated liver transplantation (LDLT) group during 
48 weeks of treatment. HCV-RNA was evaluated by the qualitative PCR method. The 
disappearance rate was calculated as follows: serum HCV-RNA disappearance case 
number/all cases in indicated time. The statistical analysis was carried out using the 
Kaplan–Meier method with the Wilcoxon assay. ST1H group was plotted as the 
HCV-RNA disappearance line between the white circle of the LDLT group and the 
black circle of the CHC group. In all cases and the ST1H group, the disappearance rate 
was statistically significant between the CHC group and the LDLT group (P < 0.05). 
Figure 2    Comparison of viral kinetics between the SG1H-CHC group and the 
SG1H-LDLT group during the 48 weeks of treatment. (a) The HCV core antigen load 
and (b) reduction rates were plotted by a straight line (SG1H-CHC group), and dotted 
line (SG1H-LDLT group). The error bar represented the standard deviation. On the 
y-axis, D0 is pretreatment, D1 and WX is time post-treatment day 1 and week X, 
respectively. The reduction rate was calculated as follows: log10HCV cAg load in 
indicated time/in D0. HCV cAg titer at the indicated time between SG1H-CHC and 
SG1H-LDLT were compared. The asterisk mark indicates a significant difference, 
P < 0.05, calculated by Mann–Whitney U-test. 
Figure 3    Comparison of viral kinetics between matched pretreatment HCV cAg 
ST1H-CHC group and ST1H-LDLT group during 48 weeks of treatment. (a) HCV core 
antigen load and (b) reduction rate were plotted by a straight line (matched SG1H-CHC 
group) and dotted line (matched SG1H-LDLT group). The error bar represents the 
standard deviation. The asterisk mark is the significant difference, P < 0.05, calculated 
by Mann–Whitney U-test. 
Table 1    Difference of characteristics between all chronic hepatitis C cases and all 
living donor liver transplantation cases 
Characteristics All-CHC (n = 64) All-LDLT (n = 16) P-value 
Age (years) 58 ± 10.8 58.8 ± 4.62 NS 
Sex (male : female) 36:28 7:9 NS 
Height (m) 1.60 ± 0.098 1.583 ± 0.010 NS 
Bodyweight (kg) 61.0 ± 11.0 54.8 ± 8.52  0.025 
Body mass index 23.6 ± 2.94 21.8 ± 2.30 0.022 
PEG-IFN dose (g) 80.1 ± 18.7 71.9 ± 33.5 0.035 
PEG-IFN/BW 1.31 ± 0.304 1.35 ± 0.708 NS 
Ribavirin dose (mg) 621.9 ± 151.7 525 ± 100 0.030 
Ribavirin/BW 10.2 ± 2.23 9.72 ± 2.04 NS 
Serotype (1:2) 45:17 15:1 0.081 
HCV cAg (fmol/L) 5773 ± 5609 23144 ± 21059 0.001 
WBC (/L) 5006.3 ± 1335 5918.8 ± 2439 NS 
RBC (104/L) 445 ± 41.1 350 ± 56.7 <0.0001 
Hemoglobin (g/dL) 13.8 ± 1.06 10.9 ± 1.85 <0.0001 
Platelet (104/L) 16.4 ± 4.48 18.5 ± 10.6 NS 
AST (U/L) 62.9 ± 35 64.3 ± 37.2 NS 
ALT (U/L) 85 ± 53.0 89.9 ± 57.1 NS 
-GTP (U/L) 62.1 ± 56.5 138.9 ± 129.1 0.013 
Ferritin (ng/dL) 218 ± 216 254 ± 259 NS 
TC (mg/dL) 169.8 ± 26.6 167.3 ± 38.8 NS 
TG (mg/dL) 105.3 ± 46.8 122.8 ± 44.8 0.069 
HDL (mg/dL) 45.2 ± 11.9 46.6 ± 14.9 NS 
LDL (mg/dL) 97.3 ± 24.3 88.8 ± 26.7 NS 
FFA (mEq/L) 0.492 ± 0.261 0.686 ± 0.299 0.019 
FPG (mg/dL) 91.9 ± 15.4 125.1 ± 56.9 0.090 
Insulin (mIU/L) 9.16 ± 5.1 8.34 ± 5.16 NS 
HOMA-IR 2.08 ± 1.22 1.75 ± 1.42 NS 
HOMA- 135.4 ± 86.2 89.7 ± 86.9 0.075 
Fibrosis 1.86 ± 1.18 0.875 ± 0.806 0.004 
Activity 1.03 ± 0.48 1.31 ± 0.48 0.067 
Data are shown as the means ± standard deviation and values, with statistical analysis 
calculated by Mann–Whitney U-test for means and Pearson’s 2-test for values. 
Normal values in laboratory tests: ALT (IU/L), 5–40; AST (IU/L), 10–40; -GTP 
(IU/L), <70 in males, <30 in females; TC (mg/dL), 150–219; TG (mg/dL), 50–149; 
FFA (mEq/L), 0.14–0.85; LDL (mg/dL), 70–139; HDL (mg/dL), 40–86 in male, 40–96 
in female; hemoglobin (g/dL), 13.5–17.6 in male, 11.3–15.2 in female; WBC (/L), 
3900–9800 in males, 3500–9100 in females; RBC (104/L), 427–570 in males, 
376–500 in females; ferritin (mg/dL), 27–320 in males, 3.4–89 in females; platelet 
(104/L), 13.1–36.2 in males, 13–36.9 in females; insulin (IU/L), 3.06–16.9; FPG 
(mg/L), 70–109. HOMA-IR, HOMA-, and BMI are described in the text. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHC, chronic 
hepatitis C; FFA, free fatty acid; FPG, fasting plasma glucose; HCV cAg, hepatitis C 
virus core antigen; HDL, high density lipoprotein; HOMA, homeostasis model 
assessment; LDL, low density lipoprotein; LDLT, living donor liver transplantation; 
PEG-IFN, pegylated interferon; RBC, red blood cell count; TC, total cholesterol; TG, 
triglyceride; WBC, white blood cell count. 
Table 2    Difference of characteristics of serotype 1 and high virus titer between 
chronic hepatitis C patients and living donor liver transplantation patients 
Characteristics ST1H-CHC (n = 42) ST1H-LDLT (n = 15) P-value 
Age (years) 58.5 ± 10.8 58.8 ± 4.78 NS 
Sex (male : female) 22:20 6:9 NS 
Height (m) 1.60 ± 0.10 1.566 ± 0.081 NS 
Bodyweight (kg) 61.8 ± 12.1 53.8 ± 7.69  0.02 
Body mass index 24.0 ± 2.78 21.9 ± 2.37 0.012 
PEG-IFN dose (g) 81.4 ± 19.5 73.3 ± 34.2 0.052 
PEG-IFN/BW 1.33 ± 0.269 1.39 ± 0.711 NS 
Ribavirin dose (mg) 642.8 ± 150.0 520 ± 101.4 0.011 
Ribavirin/BW 10.5 ± 2.13 9.80 ± 2.08 NS 
HCV cAg (fmol/L) 6969 ± 5281 24674 ± 20856 0.003 
WBC (/L) 5019.0 ± 1294 6033.8 ± 2479 NS 
RBC (104/L) 444 ± 40.1 351 ± 58.6 <0.0001 
Hemoglobin (g/dL) 13.9 ± 1.10 10.8 ± 1.88 <0.0001 
Platelet (104/L) 16.7 ± 4.68 18.9 ± 10.8 NS 
AST (U/L) 62.1 ± 31.6 64.2 ± 38.5 NS 
ALT (U/L) 84.5 ± 51.8 88.0 ± 58.6 NS 
-GTP (U/L) 64.0 ± 61.7 113.6 ± 83.1 0.036 
Ferritin (ng/dL) 206 ± 164.8 204.5 ± 188.4 NS 
TC (mg/dL) 172.6 ± 25.7 165.3 ± 39.2 NS 
TG (mg/dL) 108.2 ± 52.2 122.9 ± 46.4 NS 
HDL (mg/dL) 46.5 ± 11.9 45.4 ± 14.8 NS 
LDL (mg/dL) 97.7 ± 25.4 88.6 ± 27.8 NS 
FFA (mEq/L) 0.514 ± 0.251 0.693 ± 0.310 0.049 
FPG (mg/dL) 92.4 ± 16.4 123.7 ± 58.6 NS 
Insulin (mIU/L) 9.06 ± 5.5 8.34 ± 5.16 NS 
HOMA-IR 2.07 ± 1.31 1.86 ± 1.38 NS 
HOMA-b 128.0 ± 76.2 95.7 ± 86.5 NS 
Fibrosis 1.92 ± 1.19 0.933 ± 0.799 0.008 
Activity 1.08 ± 0.474 1.33 ± 0.488 0.098 
Data are shown as the means ± standard deviation and values, with statistical analysis 
calculated by Mann–Whitney U-test for means and Pearson’s 2-test for values. 
Normal values in laboratory tests are same as in Table 1. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHC, chronic 
hepatitis C; FFA, free fatty acid; FPG, fasting plasma glucose; HCV cAg, hepatitis C 
virus core antigen; HDL, high density lipoprotein; HOMA, homeostasis model 
assessment; LDL, low density lipoprotein; LDLT, living donor liver transplantation; 
PEG-IFN, pegylated interferon; RBC, red blood cell count; TC, total cholesterol; TG, 
triglyceride; WBC, white blood cell count. 
Table 3    Result of pegylated interferon--2b plus ribavirin therapy 
A. All cases 
Term All-CHC All-LDLT P-value 
Viral response 4 weeks 40/60 (67%) 5/12 (42%) NS 
Viral response 8 weeks 47/55 (85%) 6/12 (50%) 0.011 
Viral response 12 weeks 43/48 (90%) 6/12 (50%) 0.003 
Sustained viral response: ITT 20/42 (45%) 2/12 (20%) 0.054 
Sustained viral response: PP 20/28 (80%) 2/9 (22%) 0.008 
 
B. Serotype 1 and high virus titer cases 
Term ST1H-CHC ST1H-LDLT P-value 
Viral response 4 weeks 24/40 (67%) 5/11 (45%) NS 
Viral response 8 weeks 30/36 (83%) 5/11 (45%) 0.012 
Viral response 12 weeks 25/29 (86%) 5/11 (45%) 0.008 
Sustained viral response: ITT 8/27 (30%) 1/11 (8%) NS 
Sustained viral response: PP 8/15 (53%) 1/9 (11%) 0.029 
Non-virological respons: ITT 11/27 (41%) 5/11 (45%) NS 
Non-virological respons: PP 4/15 (27%) 4/9 (44%) NS 
Data are shown as relevant numbers/target case numbers (percentage of relevant 
numbers) with statistical analysis using Pearson’s 2-test for numbers. 
CHC, chronic hepatitis C; ITT, intention to treatment analysis; LDLT, living donor liver 
transplantation; PP, per-protocol analysis. 



